We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01110434
Recruitment Status : Completed
First Posted : April 26, 2010
Results First Posted : September 16, 2020
Last Update Posted : September 16, 2020
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Robert Miranda, Brown University

Brief Summary:
Cannabis use is a significant public health concern that disproportionately affect youth. Although promising psychosocial interventions are being developed, most youth do not benefit from these interventions alone. Given the clinical demand for effective treatments, the National Institute on Drug Abuse (NIDA) identified the critical need for data on the tolerability and potential efficacy of medications in adolescents. The purpose of this two-year study is to test if and how topiramate, a medication under intense study for treating several drugs of abuse, reduces cannabis use among teenagers. To this end, the investigators will randomize 56 nontreatment-seeking regular cannabis users (15 or 20 years old) to receive topiramate or placebo for 6 weeks. Youth will monitor their cannabis use for the 6-week period using handheld electronic diaries and complete assessments of reactivity to cannabis-related cues.

Condition or disease Intervention/treatment Phase
Cannabis Abuse Cannabis Dependence Drug: Topiramate Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents
Study Start Date : December 2009
Actual Primary Completion Date : May 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana
Drug Information available for: Topiramate

Arm Intervention/treatment
Experimental: Topiramate
Topiramate (200 mg daily)
Drug: Topiramate
Topiramate (200 mg daily)
Other Name: Topamax

Placebo Comparator: Sugar pill Drug: Placebo
Placebo (daily)

Primary Outcome Measures :
  1. Cannabis Use [ Time Frame: Weeks 1-6 ]
    Frequency of Cannabis Use (Percent Use Days Per Week)

Secondary Outcome Measures :
  1. Quantity of Cannabis Use [ Time Frame: Weeks 1-6 ]
    Total Grams of Cannabis Use Per week

  2. Amount of Cannabis Use Per Use Day [ Time Frame: Weeks 1-6 ]
    Average Grams of Cannabis Used Per Use Day

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 15 to 20 years old (inclusive)
  • Non-treatment seeking for cannabis abuse or dependence
  • Able to read English, understand their rights as provided by the informed consent process, and be willing to sign an informed consent form to participant in the study
  • If younger than 18 years old, informed consent from a parent or legal guardian is required
  • Used cannabis at least 2 days per week during the past 30 days

Exclusion Criteria:

  • Treatment seeking or a recent history of treatment for cannabis abuse or dependence
  • Endorses a current commitment to stop using cannabis
  • Clinically significant physical abnormalities as indicated by physical exam, hematological assessment, bilirubin concentration or urinalysis
  • History of renal impairment, renal stones, seizures, or unstable hypertension
  • Underweight (i.e., less than the 5th percentile) or overweight (equal to or greater than the 95th percentile), as determined by the Body Mass Index
  • Positive urine toxicology screen for narcotics, amphetamines, or sedative hypnotics or self-reported drug use, other than cannabis, alcohol or nicotine, in the past 30 days
  • Pregnant, nursing, or refusal to use reliable barrier method of birth control (e.g., condom), if female
  • Took a psychotropic medication in the past 30 days
  • Taking medications with a potential effect on cannabis use or a carbonic anhydrase inhibitor
  • Suicidal
  • A current DSM-IV-TR Axis I diagnosis other than attention- deficit/hyperactivity disorder or a disruptive behavior disorder
  • A current substance use disorder other than a cannabis, alcohol, and nicotine use disorders
  • Significant alcohol withdrawal symptoms
  • Known sensitivity to topiramate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01110434

Layout table for location information
United States, Rhode Island
Brown University, Center for Alcohol and Addiction Studies
Providence, Rhode Island, United States, 02912
Sponsors and Collaborators
Brown University
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Robert Miranda, Ph.D. Brown University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Robert Miranda, Associate Professor (Research), Brown University
ClinicalTrials.gov Identifier: NCT01110434    
Other Study ID Numbers: R01DA026778 ( U.S. NIH Grant/Contract )
R01DA026778 ( U.S. NIH Grant/Contract )
First Posted: April 26, 2010    Key Record Dates
Results First Posted: September 16, 2020
Last Update Posted: September 16, 2020
Last Verified: August 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Hypoglycemic Agents
Physiological Effects of Drugs